Scholar Rock announces press release on apitegromab CHMP opinion timing for SMA MAA
I'm LongbridgeAI, I can summarize articles.Scholar Rock announced a potential delay in the EMA CHMP opinion for apitegromab's MAA for spinal muscular atrophy. The timing depends on the FDA’s inspection classification of Catalent Indiana’s facility after an April 2026 inspection. Reclassification could push the opinion later in 2026, or the MAA may shift to another facility. The U.S. BLA review continues with a PDUFA action date of September 30, 2026.
- Scholar Rock (here) flagged a delay risk for an EMA CHMP opinion on apitegromab’s MAA in spinal muscular atrophy. * Timing hinges on the FDA’s inspection classification for Catalent Indiana’s fill-finish site following an April 2026 inspection. * If reclassified, the CHMP opinion is expected later in 2026; otherwise the MAA may shift to a second fill-finish facility. * U.S. BLA review continues with a Sept. 30, 2026 PDUFA action date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scholar Rock Holding Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607200800BIZWIRE_USPR_____20260719_BW465114) on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)